Analyst Price Targets — BIIB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 9:11 am | Mohit Bansal | Wells Fargo | $250.00 | $177.35 | TheFly | Biogen upgraded to Overweight from Equal Weight at Wells Fargo |
| April 14, 2026 12:19 am | — | Piper Sandler | $214.00 | $176.37 | TheFly | Biogen upgraded to Overweight from Neutral at Piper Sandler |
| April 10, 2026 12:54 pm | — | Morgan Stanley | $200.00 | $173.48 | TheFly | Biogen price target raised to $200 from $190 at Morgan Stanley |
| February 19, 2026 9:20 pm | Emily Field | Barclays | $185.00 | $192.08 | TheFly | Biogen initiated with an Equal Weight at Barclays |
| February 11, 2026 12:51 pm | — | Mizuho Securities | $236.00 | $188.99 | TheFly | Biogen price target raised to $236 from $207 at Mizuho |
| February 10, 2026 1:21 pm | Laura Chico | Wedbush | $187.00 | $192.72 | TheFly | Biogen price target raised to $187 from $178 at Wedbush |
| February 9, 2026 2:46 pm | — | Wolfe Research | $231.00 | $196.00 | StreetInsider | Goldman Sachs Reiterates Buy Rating on Biogen (BIIB) |
| February 9, 2026 2:43 pm | — | RBC Capital | $233.00 | $195.93 | TheFly | Biogen price target raised to $233 from $217 at RBC Capital |
| February 9, 2026 2:25 pm | — | Wolfe Research | $215.00 | $195.45 | StreetInsider | Biogen (BIIB) PT Raised to $215 at TD Cowen |
| February 9, 2026 12:23 pm | Danielle Brill | Truist Financial | $193.00 | $201.18 | TheFly | Biogen price target raised to $193 from $190 at Truist |
Latest News for BIIB
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apellis Pharmaceuticals, Inc. (NasdaqGS: APLS) to Biogen Inc. (NasdaqGS: BIIB). Under the terms of the proposed transaction, shareholders of Apellis will receive $41.00 per share in cash and a nontransferable contingent…
Biogen (NASDAQ:BIIB) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst Mohit Bansal upgraded the shares to Overweight from Equal Weight and raised his price target to $250 from $200.
BIIB, LMT, NOC, MA and MTD are five non-tech wide moat picks as durable advantages, defense demand, and digital payments growth position these stocks for resilient returns.
Biogen said on Monday it had agreed to pay up to $850 million to acquire exclusive rights in Greater China to an experimental immune disease treatment from Chinese biotech firm TJ Biopharma, giving the U.S. drugmaker worldwide rights to develop and market the treatment.
CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma (“TJ Bio”) today announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater China Region. With this agreement, Biogen now owns exclusive worldwide rights to felzartamab, which is currently being…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.